Evan Schwarzwald, DO
Cardiovascular Disease · Franklin Square, NYNPI 1164414330
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $277,253 of the $310,642 with a category attached, or 89.3%. 20 manufacturers reported payments, led by Novo Nordisk at 43.6% of the total. Reporting peaked in 2024 at $82,075 and has fallen 97.6% since, to $1,999 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $853.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$136K
- Johnson & Johnson$64K
- Amgen$48K
- Boehringer Ingelheim$25K
- Amarin Pharma, Inc.$19K
- Lilly USA, LLC$12K
- plus $8K from 14 others
What the payments were for
- Consulting fees$4,0501%
- Speaking & faculty fees$277,25389%
- Travel & lodging$12,6284%
- Food & beverage$16,7005%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $135,513 |
| Johnson & Johnson | 110 | $63,770 |
| Amgen | 38 | $47,933 |
| Boehringer Ingelheim | 36 | $24,500 |
| Amarin Pharma, Inc. | 16 | $18,965 |
| Lilly USA, LLC | 16 | $12,095 |
| Medtronic(2 entities) | 42 | $5,047 |
| Boston Scientific | 12 | $1,287 |
| AstraZeneca | 5 | $319 |
| Intuity Medical Inc | 2 | $289 |
| Cvrx, Inc. | 2 | $280 |
| Sanofi-aventis U.S. LLC | 3 | $142 |
| Preventice Services, LLC | 1 | $117 |
| Pfizer | 3 | $113 |
| Abbott | 4 | $95 |
| Scpharmaceuticals Inc. | 4 | $92 |
| Merck | 2 | $29 |
| Gilead | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$62,620
- Repatha$47,911
- Ozempic$37,318
- JARDIANCE$36,028
- Vascepa$18,505
- Wegovy$17,981
- RYBELSUS$14,448
- Reveal LINQ$1,219
- CardioInsight$674
- AURORA EV-ICD MRI SURESCAN$344
- Watchman$341
- Pogo Automatic Blood Glucose Monitoring System$289
- Barostim Neo System$280
- Claria MRI$271
- WATCHMAN Access System$244
- FARXIGA$222
- COBALT DR MRI SURESCAN$201
- Micra$162
- WATCHMAN FLX$148
- LINQ II$138
How this compares
$310,642 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $76,332 |
| XareltoRivaroxaban | 37 | $47,817 |
| EliquisApixaban | 34 | $39,939 |
| WegovySemaglutide | 26 | $37,207 |
| Repatha SureclickEvolocumab | 42 | $28,750 |
| JardianceEmpagliflozin | 22 | $27,762 |
| EntrestoSacubitril/Valsartan | 23 | $21,984 |
| FarxigaDapagliflozin Propanediol | 18 | $10,050 |
| Ezetimibe | 163 | $4,354 |
| Metoprolol Succinate | 198 | $2,356 |
| Rosuvastatin Calcium | 177 | $2,245 |
| Celecoxib | 14 | $1,483 |
| Atorvastatin Calcium | 128 | $1,252 |
| Amlodipine Besylate | 179 | $923 |
| Losartan Potassium | 92 | $899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $135,513 | $113,53988 claims |
| Johnson & JohnsonXarelto | $63,770 | $47,81737 claims |
| PfizerEliquis | $113 | $39,93934 claims |
| Boehringer IngelheimJardiance | $24,500 | $27,76222 claims |
| AstraZenecaFarxiga | $319 | $10,05018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Franklin Square
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.